List view / Grid view
The microscope slide is flat (2D), but the world around us is not – despite the flat-earth theories. We need volume information about our samples, ideally with high resolution in all three dimensions as well as over time – the fourth dimension...
The world of healthcare is rapidly evolving. With an ageing population, comes a significant increase in cancers, metabolic diseases and neurodegenerative disorders. New drug candidates are required; however drug development remains a lengthy and expensive process, with the average timeline now over 10 years and costs continuing to rise...
How times change. Up to 15 years ago, you would be hard-pressed to find a drug discovery conference with a track dedicated to phenotypic approaches. The underpinning science was called high-content imaging or analysis, being mainly confined to academic drug discovery labs and a handful of pioneers in industry. but…
Chemotherapy with cytotoxic and growth inhibitory drugs have played an important role in cancer therapy, used either alone or in combination with other treatment modalities such as surgery, radiation or biological therapy. Chemotherapy, in most instances, was the only alternative treatment for metastatic cancer – mainly given as drug combinations...
Mesenchymal stem cells (MSCs) are fibroblast-like cells that give rise to mesenchymal derivatives including bone, fat and cartilage cells. In addition to the bone marrow, they can be readily obtained from adult vascularised peripheral tissues including adipose, olfactory, respiratory tissue, and peripheral blood.
Kidneys are crucial for filtration of drugs and toxins and their proper function is essential for overall health. Unfortunately, due to disease and improper function, kidney transplantation or dialysis are necessary for millions of patients annually all over the world.1,2
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
